ArticleLung2026
Contemporary Chemotherapy Benchmarks for Molecularly Defined Advanced NSCLC: Reconstructed Individual Patient-Level Data of 22 Randomized Trials.
Article in Lung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe increasing adoption of targeted therapies over chemotherapy has made randomized controlled trials (RCT) with chemotherapy increasingly challenging in advanced NSCLC with actionable genomic alterations (AGA), particularly for rare subgroups. Contemporary chemotherapy outcomes specific to AGAs are lacking despite growing reliance on single-arm studies and external-control analyses. We sought to establish first-line platinum-doublet chemotherapy outcomes in advanced NSCLC with AGAs using data from RCTs.
methodsWe extracted objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) data from Phase 2/3 RCTs. Individual patient-level data were reconstructed from Kaplan-Meier curves to pool and compare PFS and OS across AGAs.
resultsTwenty-two RCTs (n = 2132) were included. Across most AGAs, platinum-doublet chemotherapy produced similar outcomes-pooled ORRs ranging from 28.7 to 39.0% and median PFS from 6.0 to 7.3 months. Pairwise comparisons showed better ORR/PFS for RET fusion (one trial with control arm-chemotherapy/pembrolizumab) and shorter OS for KRAS mutation versus other AGAs (logrank P<.001). Detailed pooled ORR and median PFS and OS were: ALK rearrangement (n = 461)-ORR 39.0% (95% CI 25.8-52.2), PFS 7.0 months (6.8-7.2), OS 43.0 months (32.2-inestimable); common EGFR mutation (n = 1038)-ORR 28.7% (22.3-35.1), PFS 6.0 months (5.7-6.3), OS 27.4 months (26.1-29.3); uncommon EGFR mutation (n = 61)-ORR 35.1% (12.6-57.7), PFS 6.7 months (5.2-8.4), OS 29.5 months (13.3-inestimable); EGFR exon 20 insertion (n = 330)-ORR 38.3% (21.7-55.0), PFS 7.3 months (6.9-8.6), OS 30.1 months (29.1-inestimable); KRAS mutation (n = 140)-ORR 21.7% (12.4-30.9), PFS 6.2 months (4.7-6.9), OS 10.8 months (8.8-12.7); RET fusion (n = 102)-ORR 65.0% (54.5-75.5), PFS 11.4 months (8.9-16.9), OS not available.
conclusionPlatinum-doublet chemotherapy yields remarkably consistent ORR and PFS across most advanced NSCLC with AGAs. These data provide contemporary molecularly defined benchmarks that may support interpretation of single-arm studies, development of external-control analyses, and future trial design in this rare population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.